about
Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients.A novel BRCA1 mutation in a patient with breast and ovarian cancer: A case report.Effect of ABCB1 and ABCC3 polymorphisms on osteosarcoma survival after chemotherapy: a pharmacogenetic studyFHL2 silencing reduces Wnt signaling and osteosarcoma tumorigenesis in vitro and in vivo.Influence of genetic variants in TPMT and COMT associated with cisplatin induced hearing loss in patients with cancer: two new cohorts and a meta-analysis reveal significant heterogeneity between cohorts.Characterization of the Antiglioma Effect of the Oncolytic Adenovirus VCN-01Development of a DIPG Orthotopic Model in Mice Using an Implantable Guide-Screw System.Germline TP53 variants and susceptibility to osteosarcoma.Regulation of osteosarcoma cell lung metastasis by the c-Fos/AP-1 target FGFR1.KRAS mutational status analysis of peripheral blood isolated circulating tumor cells in metastatic colorectal patients.Thymidylate synthase polymorphisms in genomic DNA as clinical outcome predictors in a European population of advanced non-small cell lung cancer patients receiving pemetrexed.Antitumoral-Lipid-Based Nanoparticles: a Platform for Future Application in Osteosarcoma therapy.PheoSeq: A Targeted Next-Generation Sequencing Assay for Pheochromocytoma and Paraganglioma Diagnostics.Strategies to design clinical studies to identify predictive biomarkers in cancer research.Activated and expanded natural killer cells target osteosarcoma tumor initiating cells in an NKG2D-NKG2DL dependent manner.The oncolytic adenovirus Δ24-RGD in combination with cisplatin exerts a potent anti-osteosarcoma activity.Zinc chelation: a metallothionein 2A's mechanism of action involved in osteosarcoma cell death and chemotherapy resistance.Calpain-6 is an endothelin-1 signaling dependent protective factor in chemoresistant osteosarcoma.Exome array analysis identifies ETFB as a novel susceptibility gene for anthracycline-induced cardiotoxicity in cancer patients.Total and mutated EGFR quantification in cell-free DNA from non-small cell lung cancer patients detects tumor heterogeneity and presents prognostic value.Methotrexate in pediatric osteosarcoma: response and toxicity in relation to genetic polymorphisms and dihydrofolate reductase and reduced folate carrier 1 expression.Cortactin (CTTN) overexpression in osteosarcoma correlates with advanced stage and reduced survival.Genome-wide association study identifies the GLDC/IL33 locus associated with survival of osteosarcoma patients.Oncolytic adenoviruses as a therapeutic approach for osteosarcoma: A new hope.Polymorphisms in miRNA processing genes and their role in osteosarcoma risk.Exome array analysis identifies GPR35 as a novel susceptibility gene for anthracycline-induced cardiotoxicity in childhood cancer.Genetic and epigenetic alterations of the cell cycle regulators and tumor suppressor genes in pediatric osteosarcomas.Memory T Cells Expressing an NKG2D-CAR Efficiently Target Osteosarcoma Cells.Recommendations for somatic and germline genetic testing of single pheochromocytoma and paraganglioma based on findings from a series of 329 patients.Matrix-Gla protein promotes osteosarcoma lung metastasis and associates with poor prognosis.Clinical involvement of catechol-O-methyltransferase polymorphisms in schizophrenia spectrum disorders: influence on the severity of psychotic symptoms and on the response to neuroleptic treatment.Doxorubicin and edelfosine lipid nanoparticles are effective acting synergistically against drug-resistant osteosarcoma cancer cells.Genome-wide association study identifies multiple new loci associated with Ewing sarcoma susceptibilityOncolytic Viruses as Therapeutic Tools for Pediatric Brain TumorsProfiling of Chemonaive Osteosarcoma and Paired-Normal Cells Identifies EBF2 as a Mediator of Osteoprotegerin Inhibition to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Induced ApoptosisRadiación ionizante recibida por pruebas de radiología intervencionista durante el tratamiento con quimioterapia intraarterial en pacientes afectos de osteosarcomaCorrelation of myelodysplastic syndromes with i(17)(q10) andTP53andSETBP1mutationsDiagnóstico inesperado en un varón de 16 años con dolor de espaldaA new mutation in the hMSH2 gene in a Spanish Lynch syndrome familySpinal extradural arachnoid cysts in lymphedema-distichiasis syndrome
P50
Q27851470-0DA1E5A6-C4A2-483A-B39B-3EB28183CEB9Q27852587-C0C8DE86-6146-4A1F-B36E-203E042D06BCQ28744127-1ED703B0-9BFF-4DEC-8D08-F7130803CCAEQ34575984-5CB23DA6-BDF2-4876-AD86-7D5650BAC0CAQ34797430-2A963055-C72E-47B9-A2E9-98F3C3B85699Q35903437-35090117-8935-4E99-AEB8-6D1D9FFF8D9DQ36255670-8210CF5C-A008-4209-B72B-B1119EE4CE43Q36294747-EEF4D539-BBAF-482D-8640-F49D2BE42E79Q36398042-A2F67DD2-3283-4B2B-8746-E10527587540Q37269424-78E53B13-7F58-4F01-97AE-C18A31FB777DQ37718808-D0C95463-6F37-4892-902D-3D710A980453Q38616717-138B1C7F-211F-42CC-AFCF-42E8842A43A0Q38759395-CAE0C685-C3FB-4BCF-BFEB-5F093FF41A5AQ38770451-6F7A3015-E9E4-441A-ABFF-F63FC7EE0C33Q38843489-90DE9414-5290-471A-95A0-214D78B6DADFQ39003657-B8BE6C81-F5EF-4D32-B864-2AB35998F9EEQ39070928-4C08CB69-A304-4A9E-A9F9-C45BAF5CF735Q39522909-9E20DA2F-700F-48FA-A874-91E6F98B68F6Q40039502-AD4FCA1D-1EC4-4A83-82CD-EBA820508790Q40393934-682A87F2-F9C2-40A0-80B2-B89389105292Q43889056-EBFDD563-152A-43B3-9E55-63BECA21951BQ46403981-7FC84D42-B744-408F-A171-7F14B69C9C34Q46904091-BEC80649-414A-4D95-84E3-5DBC851C978AQ47095296-CF162D14-3A30-4A46-B805-24BA8E05C948Q47438993-F83B3F2A-016B-41E5-BD4A-51473D3173B1Q47726410-52C82613-9D4B-4085-92EA-877217D0887FQ47897718-C91B1B86-F10F-4FAA-BA93-72C817257410Q48738476-661DE046-AB3B-4F0B-90CF-4C111909FEC6Q50438414-002B7BB5-4C8F-4FB0-AACD-B8FC1EFBDECEQ50853780-B582DE45-3E70-4D1A-8187-36EDE87B7EDCQ51919751-14D3B0FC-5E94-4C40-82A5-62D36CC4B2FEQ52938914-824113A3-5E47-4CAD-BDF8-1C1F69EA2F05Q56346041-B5D853E1-C7EE-4A29-9A4B-D04164B01A3FQ56892727-827C14BB-0BA4-4F61-A4B5-855612CB878CQ58051500-B0679FC6-FA20-4A02-98EB-9EE5956B41AFQ58074522-1154CAFE-E664-47D5-8D22-D4238FA1E1A3Q58074618-CCB3D113-8D36-44B9-97F7-24F2CE043965Q58074795-13B2D74A-9218-4522-BF53-B65E1507783AQ58074835-9CD19AD1-0FD5-46AD-A1AF-9E9697D975F8Q58074858-4E824ED2-3079-4FAA-A086-85CD18D7B803
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Ana Patiño-García
@ast
Ana Patiño-García
@en
Ana Patiño-García
@es
Ana Patiño-García
@nl
type
label
Ana Patiño-García
@ast
Ana Patiño-García
@en
Ana Patiño-García
@es
Ana Patiño-García
@nl
prefLabel
Ana Patiño-García
@ast
Ana Patiño-García
@en
Ana Patiño-García
@es
Ana Patiño-García
@nl
P106
P21
P31
P496
0000-0002-4066-8203